Bisphosphonates in the treatment of osteoporosis

Journal of Clinical Rheumatology

Volumn 3, Issue 2 SUPPL., 1997, Pages

  Hochberg, Marc C ^a,b,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MSTF 8 34 ^*  (United States)

Author keywords

Alendronate; Bisphosphonates; Etidronate; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ETIDRONIC ACID; PLACEBO; VITAMIN D;

ADULT; AGED; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ESOPHAGITIS; FEMALE; GASTROINTESTINAL TOXICITY; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERTEBRA FRACTURE;

EID: 0030975024     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/00124743-199704001-00009     Document Type: Conference Paper

References (13)

1. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996;18:75-85.
2. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest 1996;97: 2692-6.
3. Ott SM. Clinical effects of bisphosphonates in involutional osteoporosis. J Bone Miner Res 1993;(2 suppl)8:S597-S606.
4. Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265-1271.
5. Storm T, Kollerup G, Thamsborg G, et al. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis. J Rheumatol 1996;23:1560-1564.
6. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323:73-79.
7. Harris ST, Watts NB, Jackson RD, et al. Four-year study of intermittent cyclical etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993;95: 557-567.
8. Watts NB, Miller PD, Licata AA, et al. Seven years of cyclical etidronate: continued improvement in spine BMD and progressive decline in vertebral fracture incidence. Bone 1995;17:617.
9. Axelrod DW. Long term safety and efficacy of cyclical etidronate therapy for osteoporosis. Osteoporos Jpn 1996;4:211-221.
10. Liberman UA, Weiss SR, Broll J, et al., for the Alendronate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-1443.
11. Black DM, Reiss TF, Nevitt MC, et al., for the Fracture Intervention Trial Research Group. Design of the Fracture Intervention Trial. Osteoporos Int 1993;(suppl)3:S29-S39.
12. Black DM, Cummings SR, Karpf DB, et al., for the Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate of risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
13. de Groen PC, Lubbe DF, Hirsch LF, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016-1021.